Qiagen

Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Established in 1984, the company is headquartered in Venlo, the Netherlands. Qiagen's products are sold in more than 130 countries.

History

Qiagen was founded in 1984 by a team of scientists at the University of Düsseldorf in Germany. The company's first product, the QIAamp Viral RNA Mini Kit, was launched in 1996 and is still one of the company's most popular products today.

In 1996, Qiagen went public on the NASDAQ stock exchange. In 2004, the company acquired artus GmbH, a leading provider of PCR-based testing solutions, and in 2007, it acquired Digene Corporation, a leader in molecular diagnostic testing for HPV and other sexually transmitted infections.

Products and Services

Qiagen offers a broad range of products for molecular diagnostics, applied testing, academic and pharmaceutical research. These include sample preparation technologies, assay technologies, bioinformatics software and services, and automation systems.

Some of the company's most popular products include the QIAamp Viral RNA Mini Kit, the QIAsymphony SP/AS system, and the QuantiFERON-TB Gold Plus test.

Financial Performance

As of 2020, Qiagen reported revenues of $1.87 billion, an increase of 23% compared to the previous year. The company's net income for the year was $190.4 million.

See Also

• Molecular diagnostics
• Applied testing
• Academic research
• Pharmaceutical research

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!